Chinese CRDMOs are expected to see a temporary reprieve this year following the delay of the Biosecure Act in 2024, said UOB Kay Hian.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback